Skip to main content

Advertisement

SpringerLink
Log in

Gene patents in Australia: where do we stand?

  • Patents
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

The provision of a patent system that protects innovators and researchers while ensuring reasonable access to emerging technologies and medical treatments are the key objectives of the Australian government's response to three important reports concerning Australia's patent system and gene patents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kirin-Amgen Inc v Board of Regents of University of Washington (1995) 33 IPR 557.

  2. Genetics Institute Inc v Kirin-Amgen Inc (1996) 34 IPR 513.

  3. Senate Committees inquiry on the Patent Amendment (Human Genes and Biological Materials) Bill 2010. Submissions received by the Committee. http://www.aph.gov.au/Parliamentary_Business/Committees/Senate_Committees?url=legcon_ctte/patent_amendment/submissions.htm

  4. Australian Law Reform Commission. ALRC Submission to Senate Standing Committee on Community Affairs Inquiry into Gene Patents (ALRC, 18 March 2009). http://www.alrc.gov.au/senate-standing-committee-community-affairs-inquiry-gene-patents

  5. Australian Law Reform Commission. Advisory Council on Intellectual Property Review of Patentable Subject Matter (ALRC, December 2010). http://www.acip.gov.au/library/ACIP%20PSM%20final%20report%204%20Feb%202011.pdf

  6. Australian Law Reform Commission. Genes and Ingenuity: Gene Patenting and Human Health (ALRC, 30 August 2004). http://www.alrc.gov.au/publications/report-99

  7. Anonymous. Australian Government Response to Senate Community Affairs References Committee Gene Patents Report (23 November 2011) http://www.ipaustralia.gov.au/46106/Australian_Government_Response_to_Senate_Committee_Gene_Patents_Report.pdf

  8. Cancer Voices Australia & Anor v Myriad Genetics Inc & Ors, Federal Court of Australia, NSD643 (2010).

  9. Myriad Genetics, Inc. In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene. Australian patent no. 686004 (1995). http://pericles.ipaustralia.gov.au/ols/auspat/applicationDetails.do?applicationNo=1995033212

  10. http://www.cafc.uscourts.gov/images/stories/opinions-orders/10-1406.pdf

Download references

Author information

Authors and Affiliations

  1. David P. Simmons and Mark E. Wickham are at Phillips Ormonde Fitzpatrick, Melbourne, Victoria, Australia.,

    David P Simmons & Mark E Wickham

Authors
  1. David P Simmons
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark E Wickham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to David P Simmons or Mark E Wickham.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simmons, D., Wickham, M. Gene patents in Australia: where do we stand?. Nat Biotechnol 30, 323–324 (2012). https://doi.org/10.1038/nbt.2173

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2173

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation